Systematic Review of Primary Outcome Measurements for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Randomized Controlled Trials.
Kim, Do-Young, Lee, Jin-Seok, Son, Chang-Gue · Journal of clinical medicine · 2020 · DOI
Quick Summary
This study examined how researchers measure treatment effects in ME/CFS clinical trials by reviewing 52 studies published between 1996 and 2020. The researchers found that most trials rely on patient questionnaires asking about fatigue, physical function, and quality of life rather than objective blood tests or physical measurements. Three questionnaires—the SF-36, Checklist Individual Strength, and Chalder Fatigue Questionnaire—were used most often to track whether treatments worked.
Why It Matters
Understanding which measurement tools researchers use in clinical trials is crucial because it affects whether treatments are correctly identified as effective or ineffective for ME/CFS. This review helps identify gaps in outcome standardization and demonstrates that the field heavily depends on patient self-report rather than objective biomarkers, which has implications for trial design, regulatory approval, and treatment validation going forward.
Observed Findings
96.2% of ME/CFS RCTs relied on patient-reported outcome measures rather than objective biomarkers or clinical measurements.
The SF-36 was the single most frequently used primary outcome (16 RCTs), followed by CIS (14 RCTs) and CFQ (11 RCTs).
Outcome measurement preferences shifted over time: CGI and SF-36 dominated early trials (1996-2010), while CIS and MFI became preferred in recent trials (2016-2020).
59.6% of RCTs used only one primary outcome measure, while others used two or more outcome measures simultaneously.
Only 7.7% of trials (4 RCTs) used behavioral measurements, predominantly in adolescent populations.
Inferred Conclusions
ME/CFS clinical trials lack standardized primary outcome measures, with researchers choosing from diverse patient-reported questionnaires rather than consensus biomarkers.
The field's heavy reliance on subjective patient assessment reflects the unknown etiology of ME/CFS and absence of validated objective diagnostic criteria.
There is a meaningful gap between the high heterogeneity of outcome measures used and the need for standardized, validated assessment tools to improve trial comparability and evidence synthesis.
Remaining Questions
Which of these outcome measures most accurately capture clinically meaningful improvement from the patient's perspective in ME/CFS?
What This Study Does Not Prove
This review does not prove which outcome measures are most valid, reliable, or clinically meaningful for ME/CFS—it only documents which ones were used. It does not establish which assessment tools best capture real patient improvement or whether current measurements adequately reflect the complexity of ME/CFS pathophysiology. The study also does not determine whether the shift toward CIS and MFI in recent years represents better science or simply changing research trends.
Why has the field not converged on standardized primary outcome measures despite decades of clinical trials, and what barriers prevent consensus?
Are the recent shifts toward CIS and MFI based on superior psychometric properties, or are they reflecting other research trends independent of validity?
What validated objective biomarkers (if any) should supplement or replace patient-reported outcomes in future ME/CFS clinical trials?